Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes

Summary

This study is designed to evaluate the safety and efficacy of PN2034 in insulin-dependent type 2 diabetics as measured by the change in average daily insulin dose from baseline to week 12. The effects of PN2034 on HbA1c, fasting plasma glucose (FPG), and lipid levels will also be measured.

Timeline

Start

2005-05

Primary completion

—

Completion

2007-04

Drugs

Indications